Modern Obstructive HCM Care: From Unmet Needs to Individualized Myosin Inhibitor Therapy
Anjali Owens, MD
Ahmad Masri, MD, MS
Safety in oHCM Therapy: How and When to Transition Treatment?
Vous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
Antoine Lanot, MD, PhD
Gil Yosipovitch, MD
Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
Richard Lafayette, MD, FACP
Ankana Daga, MD
Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
Michael Nassif, MD, MSc
Cracking the Code of Obstruction: Unmet Needs in oHCM
When ß-Blockers Fall Short in oHCM: Time for a New Approach?
Molecular Precision: How Myosin Inhibitors Redefine Control
Inside the IgAN Clinic: Shared Decision-Making Into Practice
Jonathan Barratt, MD, PhD
CKD-aP: Beyond the Surface
Leonie Kraft, MD
Kappa-Opioid Settings: Real-World Evidence Insights
Lucio Manenti, MD, PhD
Emilio Sanchez, MD, PhD
Quantifying CKD-aP: Tools for Better Care
James Burton, DM, FRCP
Is CKD-aP Hiding in Your Dialysis Center?
Elevating CKD-aP Care: New Frontier
Future Directions in Managing Hyperkalemia in CKD and HF
Javed Butler, MD, MPH, MBA
Optimizing Hyperkalemia Management: Clinical Implications and Risk Assessment